tiprankstipranks
Trending News
More News >
Vicore Pharma Holding AB (SE:VICO)
:VICO

Vicore Pharma Holding AB (VICO) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Vicore Pharma Holding AB

(Frankfurt:VICO)

Rating:45Neutral
Price Target:
Vicore Pharma Holding AB's stock is evaluated at a moderate level, reflecting its strong liquidity and financial resilience amidst continued net losses typical for biotech R&D phases. The technical analysis indicates potential short-term stability, while valuation remains tricky due to the negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Vicore Pharma Holding AB (VICO) vs. iShares MSCI Sweden ETF (EWD)

Vicore Pharma Holding AB Business Overview & Revenue Model

Company DescriptionVicore Pharma Holding AB (VICO) is a Sweden-based pharmaceutical company focused on the development of innovative therapies for rare lung diseases and related indications. The company's core products are centered around its proprietary angiotensin II type 2 receptor (AT2R) agonist platform, which aims to address unmet medical needs in pulmonary and fibrotic diseases. Vicore Pharma's lead product candidate, VP01 (C21), is being developed for conditions such as idiopathic pulmonary fibrosis (IPF) and COVID-19-induced acute respiratory distress syndrome (ARDS).
How the Company Makes MoneyVicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.

Vicore Pharma Holding AB Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue109.35M0.000.000.000.00
Gross Profit109.35M-3.42M-3.61M-3.60M-3.54M
EBITDA-168.88M-317.47M-286.20M-293.13M-143.77M
Net Income-168.63M-310.94M-288.42M-296.48M-146.86M
Balance Sheet
Total Assets1.20B497.84M338.01M451.17M406.51M
Cash, Cash Equivalents and Short-Term Investments1.16B482.77M261.74M371.20M318.62M
Total Debt0.000.0065.00K320.00K140.00K
Total Liabilities73.78M42.45M48.92M67.85M52.00M
Stockholders Equity1.13B455.39M289.08M383.32M354.51M
Cash Flow
Free Cash Flow-164.95M-448.62M-302.92M-265.17M-122.94M
Operating Cash Flow-164.95M-249.58M-299.92M-265.17M-119.94M
Investing Cash Flow149.04M-144.46M74.00M-7.00M4.00M
Financing Cash Flow834.06M470.86M187.04M318.18M176.97M

Vicore Pharma Holding AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.77
Price Trends
50DMA
8.15
Negative
100DMA
7.82
Negative
200DMA
8.00
Negative
Market Momentum
MACD
-0.17
Positive
RSI
43.24
Neutral
STOCH
48.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Negative. The current price of 7.77 is below the 20-day moving average (MA) of 8.20, below the 50-day MA of 8.15, and below the 200-day MA of 8.00, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 48.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VICO.

Vicore Pharma Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
kr1.39B5.27152.78%1533.99%
51
Neutral
kr2.38B
9.53%41.19%
49
Neutral
AU$2.49B4.37-64.25%2.83%36.51%13.14%
48
Neutral
kr1.06B-48.22%67.70%
47
Neutral
kr1.75B-42.24%-19.44%
46
Neutral
kr2.39B-45.80%-0.57%-39.92%
45
Neutral
kr1.81B-40.15%63.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:VICO
Vicore Pharma Holding AB
7.73
-10.85
-58.40%
SE:HNSA
Hansa Biopharma AB
28.04
-20.94
-42.75%
SE:BINV
BioInvent International AB
36.35
4.25
13.24%
SE:SANION
Saniona AB
10.20
6.69
190.60%
SE:XSPRAY
Xspray Pharma AB
48.30
-30.26
-38.52%
SE:SYNACT
SynAct Pharma AB
21.20
12.28
137.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025